Your browser doesn't support javascript.
loading
European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered?
Nielsen, J; Vestergaard, L S; Richter, L; Schmid, D; Bustos, N; Asikainen, T; Trebbien, R; Denissov, G; Innos, K; Virtanen, M J; Fouillet, A; Lytras, T; Gkolfinopoulou, K; Heiden, M An der; Grabenhenrich, L; Uphoff, H; Paldy, A; Bobvos, J; Domegan, L; O'Donnell, J; Scortichini, M; de Martino, A; Mossong, J; England, K; Melillo, J; van Asten, L; de Lange, M Ma; Tønnessen, R; White, R A; da Silva, S P; Rodrigues, A P; Larrauri, A; Mazagatos, C; Farah, A; Carnahan, A D; Junker, C; Sinnathamby, M; Pebody, R G; Andrews, N; Reynolds, A; McMenamin, J; Brown, C S; Adlhoch, C; Penttinen, P; Mølbak, K; Krause, T G.
Afiliación
  • Nielsen J; Statens Serum Institut, Copenhagen, Denmark. Electronic address: nls@ssi.dk.
  • Vestergaard LS; Statens Serum Institut, Copenhagen, Denmark.
  • Richter L; Austrian Agency for Health and Food Safety, Vienna, Austria.
  • Schmid D; Austrian Agency for Health and Food Safety, Vienna, Austria.
  • Bustos N; Sciensano, Brussels, Belgium.
  • Asikainen T; Sciensano, Brussels, Belgium.
  • Trebbien R; Statens Serum Institut, Copenhagen, Denmark.
  • Denissov G; National Institute for Health Development, Tallinn, Estonia.
  • Innos K; National Institute for Health Development, Tallinn, Estonia.
  • Virtanen MJ; Finnish National Institute for Health and Welfare, Helsinki, Finland.
  • Fouillet A; French Public Health Agency (Santé Publique France), Saint-Maurice, France.
  • Lytras T; Hellenic Centre for Disease Control and Prevention, Athens, Greece.
  • Gkolfinopoulou K; Hellenic Centre for Disease Control and Prevention, Athens, Greece.
  • Heiden MA; Robert Koch Institute, Berlin, Germany.
  • Grabenhenrich L; Robert Koch Institute, Berlin, Germany.
  • Uphoff H; Hessisches Landesprüfungs- und Untersuchungsamt im Gesundheitswesen, Dillenburg, Germany.
  • Paldy A; National Public Health Institute, Budapest, Hungary.
  • Bobvos J; Ministry of Human Capacities, Budapest, Hungary.
  • Domegan L; Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.
  • O'Donnell J; Health Service Executive - Health Protection Surveillance Centre, Dublin, Ireland.
  • Scortichini M; Dipartimento Epidemiologia del S.S.R., Lazio - ASL Roma 1, Rome, Italy.
  • de Martino A; Ministero della Salute, Rome, Italy.
  • Mossong J; Laboratoire National de Santé, Luxembourg.
  • England K; Directorate for Health Information and Research, Pieta, Malta.
  • Melillo J; Department of Health Regulation, Pieta, Malta.
  • van Asten L; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • de Lange MM; National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
  • Tønnessen R; Norwegian Institute of Public Health, Oslo, Norway.
  • White RA; Norwegian Institute of Public Health, Oslo, Norway.
  • da Silva SP; Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Rodrigues AP; Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
  • Larrauri A; National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP), Carlos III Health Institute, Madrid, Spain.
  • Mazagatos C; National Centre of Epidemiology, CIBER Epidemiología y Salud Pública (CIBERESP), Carlos III Health Institute, Madrid, Spain.
  • Farah A; Public Health Agency of Sweden, Stockholm, Sweden.
  • Carnahan AD; Public Health Agency of Sweden, Stockholm, Sweden.
  • Junker C; Federal Statistical Office, Neuchâtel, Switzerland.
  • Sinnathamby M; Public Health England, Colindale, United Kingdom.
  • Pebody RG; Public Health England, Colindale, United Kingdom.
  • Andrews N; Public Health England, Colindale, United Kingdom.
  • Reynolds A; Health Protection Scotland, Glasgow, United Kingdom.
  • McMenamin J; Health Protection Scotland, Glasgow, United Kingdom.
  • Brown CS; World Health Organization, Regional Office for Europe, Copenhagen, Denmark.
  • Adlhoch C; European Centre for Disease Prevention and Control, Solna, Sweden.
  • Penttinen P; European Centre for Disease Prevention and Control, Solna, Sweden.
  • Mølbak K; Statens Serum Institut, Copenhagen, Denmark; Department of Veterinary and Animal Science, Faculty of Health and Medical Science, University of Copenhagen, Copenhagen, Denmark.
  • Krause TG; Statens Serum Institut, Copenhagen, Denmark.
Clin Microbiol Infect ; 25(10): 1266-1276, 2019 Oct.
Article en En | MEDLINE | ID: mdl-30790685
OBJECTIVES: Weekly monitoring of European all-cause excess mortality, the EuroMOMO network, observed high excess mortality during the influenza B/Yamagata dominated 2017/18 winter season, especially among elderly. We describe all-cause excess and influenza-attributable mortality during the season 2017/18 in Europe. METHODS: Based on weekly reporting of mortality from 24 European countries or sub-national regions, representing 60% of the European population excluding the Russian and Turkish parts of Europe, we estimated age stratified all-cause excess morality using the EuroMOMO model. In addition, age stratified all-cause influenza-attributable mortality was estimated using the FluMOMO algorithm, incorporating influenza activity based on clinical and virological surveillance data, and adjusting for extreme temperatures. RESULTS: Excess mortality was mainly attributable to influenza activity from December 2017 to April 2018, but also due to exceptionally low temperatures in February-March 2018. The pattern and extent of mortality excess was similar to the previous A(H3N2) dominated seasons, 2014/15 and 2016/17. The 2017/18 overall all-cause influenza-attributable mortality was estimated to be 25.4 (95%CI 25.0-25.8) per 100,000 population; 118.2 (116.4-119.9) for persons aged 65. Extending to the European population this translates into over-all 152,000 deaths. CONCLUSIONS: The high mortality among elderly was unexpected in an influenza B dominated season, which commonly are considered to cause mild illness, mainly among children. Even though A(H3N2) also circulated in the 2017/18 season and may have contributed to the excess mortality among the elderly, the common perception of influenza B only having a modest impact on excess mortality in the older population may need to be reconsidered.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza B / Mortalidad / Gripe Humana Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus de la Influenza B / Mortalidad / Gripe Humana Tipo de estudio: Prognostic_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Female / Humans / Male / Middle aged País/Región como asunto: Europa Idioma: En Revista: Clin Microbiol Infect Asunto de la revista: DOENCAS TRANSMISSIVEIS / MICROBIOLOGIA Año: 2019 Tipo del documento: Article Pais de publicación: Reino Unido